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Abstract
Background: Autoimmune retinal degeneration may occur in patients who present with sudden or, less
commonly, subacute loss of vision of retinal origin, associated with an abnormal ERG, through the action
of autoantibodies against retinal proteins. Often the patients are initially diagnosed with or suspected of
having a paraneoplastic retinopathy (PR), such as cancer-associated retinopathy (CAR). However, there is
limited information on the occurrence, the specificity of autoantibodies in these patients, and their
association with clinical symptoms.
Methods: Sera were obtained from 193 retinopathy patients who presented with clinical symptoms
resembling PR or autoimmune retinopathy (AR), including sudden painless loss of vision, typically
associated with visual field defects and photopsias, and abnormal rod and/or cone responses on the
electroretinogram (ERG). Sera were tested for the presence of anti-retinal autoantibodies by Western
blot analysis using proteins extracted from human retina and by immunohistochemistry. Autoantibody
titers against recoverin and enolase were measured by ELISA.
Results: We identified a higher prevalence of anti-retinal autoantibodies in retinopathy patients. Ninety-
one patients' sera (47.1%) showed autoantibodies of various specificities with a higher incidence of
antibodies present in retinopathy patients diagnosed with cancer (33/52; 63.5%; p = 0.009) than in
retinopathy patients without cancer (58/141; 41.1%). The average age of PR patients was 62.0 years, and
that of AR patients was 55.9 years. Autoantibodies against recoverin (p23) were only present in the sera
of PR patients, autoantibodies against unknown p35 were more common in patients with AR, while anti-
enolase (anti-p46) autoantibodies were nearly equally distributed in the sera of patients with PR and those
with AR. In the seropositive patients, the autoantibodies persisted over a long period of time – from
months to years. A rebound in anti-recoverin autoantibody titer was found to be associated with
exacerbations in visual symptoms but not in the recurrence of cancer. When compared to sera from
healthy subjects, autoantibodies against retinal proteins from both groups of patients were cytotoxic to
retinal cells, indicating their pathogenic potential.
Conclusions: These studies showed that patients with sudden or subacute, unexplained loss of vision of
retinal origin have anti-retinal antibodies in a broad range of specificity and indicate the need for
autoantibody screening. Follow-up tests of antibody levels may be useful as a biomarker of disease activity
associated with worsening of vision. Moreover, the heterogeneity in autoantibody specificity may explain
the variation and complexity of clinical symptoms in retinopathy patients.
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Background
The causes of acquired retinal diseases are poorly under-
stood, although some patients appear to have an autoim-
mune component contributing to the pathogenicity [1,2].
In these patients, serum antibodies have been associated
with loss of vision, but the precise role of the autoantibod-
ies has not been fully established. Indeed, the occurrence,
relative frequency, and specificity of these autoantibodies
are unknown.
Paraneoplastic retinopathies (PR), including cancer-asso-
ciated retinopathy (CAR), in which retinal degeneration
occurs in the presence of systemic cancer, have been the
most intensively studied group of autoimmune retinopa-
thies. Patients with CAR possess autoantibodies that react
with retinal proteins, including recoverin (23 kDa) and α-
enolase (46 kDa) [3,4]. Other autoantibodies against ret-
inal proteins have also been reported, such as neurofila-
ment proteins, heat-shock protein 70, TULP1 protein, 40-
kDa insoluble protein, and others, but their role in the
pathogenicity of acquired retinal diseases has not been
established [3,5-9]. Autoantibodies binding to bipolar
cells have been linked to the melanoma-associated retin-
opathy (MAR) syndrome [10-12]. However, autoantibod-
ies with the same specificity have recently been described
in a CAR patient [13]. Autoantibodies with other specifi-
cities were also found in the sera of patients with MAR
[11,14]. In addition, anti-recoverin antibodies have been
reported in patients with non-cancer retinopathy [15,16]
and in some patients without visual symptoms, who have
small-cell carcinoma of the lung [17].
In recent years, retinopathies without underlying neo-
plasm at the time of testing and enigmatic retinopathies
with an abnormal electroretinogram (ERG) have been
described, in which patients share certain clinical and
immunological features of PR [15,18-20]. If autoantibod-
ies are detected, and if cancer is not detected on initial
evaluation or does not occur within the next several
months after the detection of autoantibodies, the term
autoimmune retinopathy (AR) is used. For example,
autoantibodies of AR patients label the inner plexiform
layer [18] or Müller cells (described as a 35-kDa retinal
antigen) in the retina [19]. Findings from these reports of
individual case indicate that AR demonstrates diverse clin-
ical and immunological features. The relative incidence of
anti-retinal autoantibodies associated with retinopathy is
unclear.
We believe that circulating autoantibodies against retinal
antigens may contribute to retinal dysfunction and degen-
eration, especially in those patients who do not have a
genetic (familial) basis for their retinopathy. We under-
took the current study to examine the occurrence and the
specificity of autoantibodies in a cohort of 193 retinopa-
thy patients presenting with sudden or less commonly,
subacute loss of vision and abnormal ERG in association
with diagnosed or suspected cancer, and to identify any
clinical-immunological associations.
Methods
Patients and source of antibodies
We collected blood samples from 193 patients who pre-
sented with clinical symptoms that resembled PR (includ-
ing CAR syndrome) or AR. These patients presented with
sudden or, less commonly, subacute painless loss of
vision, typically associated with visual field defects and
photopsias. They were all examined by ophthalmologists
who diagnosed retinal disease of unexplained origin and
referred them for this study. The findings of abnormal rod
and/or cone responses on the ERG often triggered the sus-
picion of PR or AR. Patients who had ocular trauma, active
eye inflammation, retinal infection, retinal detachment,
retinal surgery, or a family history of retinal degeneration
were excluded from the study. Sera were prepared from
blood and stored at -80°C prior to immunological tests.
Samples were collected between 1993 and 2002 from
patients primarily from US eye clinics: Portland, Oregon
(59 patients); Chicago, Illinois (26 patients); Iowa City,
Iowa (27 patients); Madison, Wisconsin (17 patients);
and other US clinics, Canada, Europe, and Australia (64
patients). The subjects represented 82 men and 111
women, ranging between 19 and 82 years (mean age: 58.8
years). The patients were divided into two groups: 52 with
PR, who presented CAR and MAR symptoms with con-
firmed systemic cancer, and 141 with non-paraneoplastic
AR, whose cancer screening by the referring physician was
negative. For controls, we used the sera from 79 healthy
age- and sex-matched volunteer subjects (47 men and 32
women) who had no vision loss at the time of collection.
Investigations were performed according to the guidelines
of the "Declaration of Helsinki". The Oregon Health &
Science University Institutional Review Board approved
the project and informed consent was obtained at the
time of blood collection.
Antibody testing
Western blotting
Initial screening of sera was performed using retinal pro-
teins that were extracted from a human retina, with 1%
octyl glucoside in phosphate/saline buffer (PBS), pH 7.2.
The proteins were separated by SDS-gel electrophoresis on
a 10% gel and transferred to an Immobilon membrane
(Millipore, Bedford, Massachusetts). Individual strips
containing retinal proteins were blocked with 10% nor-
mal goat serum, 1% bovine serum albumin in PBS for 1
hr, and then probed with 1:100 diluted serum (1 hr) fol-
lowed by a 1-hr incubation with anti-human IgG (H and
L chain) conjugated to alkaline phosphatase (Sigma, St.BMC Ophthalmology 2004, 4 http://www.biomedcentral.com/1471-2415/4/5
Page 3 of 9
(page number not for citation purposes)
Louis, MO). Color reaction was developed by adding the
phosphatase substrate until dark bands, appeared in com-
parison to the positive control. Blots were run and exam-
ined in a masked fashion. As a positive control, we used a
reference human serum containing anti-recoverin anti-
bodies diluted 1:100. As a negative control, we omitted
serum and applied only a secondary antibody.
Immunocytochemistry
The second specificity test was performed using human-
donor retina embedded in sucrose and frozen in OCT
medium. Ten µm cryosections were fixed in 2% parafor-
maldehyde or were left unfixed. The sections were treated
with a blocking solution (1% BSA, 1% normal goat serum
in PBS) for 1 hr followed by a 20-minute incubation with
0.25 % Triton-X-100 to permeabilize the tissue. Then a
1:100 diluted serum from a patient was added for 1 hr.
The sections were washed and then incubated with a
1:2000 diluted biotinylated anti-human IgG (H and L
chain) for 1 hr. After the sections were washed, a 1:5000
diluted streptavidin HRP was added for 30 minutes. All
reagents were purchased from Zymed (San Francisco, CA).
Color reaction was developed by adding a DAB peroxi-
dase substrate (PIERCE, Rockford, IL). Controls consisted
of retinal sections that were treated with either a 1:100
diluted serum from a control (negative control) or a 1:100
diluted serum from a CAR patient with anti-recoverin
autoantibodies (positive control); or a secondary anti-
body only. Sections were evaluated for positive cell labe-
ling in a light microscope by a masked observer.
ELISA for anti-recoverin and anti-enolase antibodies
Microtiter plates were coated with 100 ng/well of bovine
recoverin or α-enolase in 0.1 M Tris-HCl buffer, pH 9.0
overnight at room temperature. After blocking with 1%
BSA in PBS for 1 hr, 100 µl of serially diluted patients'
serum was added to each well, followed by a 1-hr incuba-
tion with anti-human IgG conjugated to peroxidase
(Zymed). Color reaction was developed 30 min later after
incubation with the peroxidase substrate (2,2'-azino-bis-
(3-ethylbenz-thiazoline-6-sulfonic acid) in 0.1 M citrate-
phosphate buffer, pH 4.5, containing 3% H2O2 and meas-
ured at 405 nm using a Bio-Rad Microplate Reader.
Cytotoxicity assay
To test the cytotoxic effect of antibodies from patients, we
used a colorimetric MTT cytotoxicity test as described by
Adamus et al. [21]. Twenty-eight random samples of sera
were taken from each group of subjects for analysis.
Serum antibodies were purified by ammonium sulfate
precipitation, and the purity was checked by SDS-gel elec-
trophoresis. E1A.NR3 retinal cells at a density of 104 cells/
well in 200 µl DMEM medium were grown with purified
serum IgG from patients and controls, at 150 µg/ml for 48
hrs.
Statistical analysis
Significant differences between groups were assessed
using the nonparametric Mann-Whitney U test and Chi-
square test. A p value <0.05 was considered significant.
Results
Antibody specificity to retinal antigens
We determined the occurrence of autoantibodies against
retinal antigens (anti-retinal antibodies) in 193 patients
who presented with painless loss of vision, photopsia,
and abnormal ERG. Of the 193 sera, 91 (47.1%) showed
the presence of anti-retinal antibodies as measured by
Western blot analysis of human retinal extracts and by
immunocytochemical analysis of sections of human reti-
nas. In the majority of cases, Western blotting was suffi-
cient to identify anti-retinal antibodies. However, anti-
bipolar cell antibodies, which were negative on the blot,
could be identified only by immunocytochemistry (data
not shown). Typically, a serum demonstrated immunos-
taining of a single protein band on the blot. When the
serum was suspected to react with known proteins – such
as recoverin, arrestin, α-enolase, rhodopsin, transducin,
carbonic anhydrase, phosphodiesterase, and IRBP – its
reactivity was confirmed by the additional incubation of
serum with a purified protein on a blot in a separate
experiment.
In our studies, 27% of patients were diagnosed with can-
cer, including small cell carcinoma of the lung, endome-
trial carcinoma, colon carcinoma, breast carcinoma,
ovarian carcinoma, skin melanoma, and others (Table 1
and 2). The average age of patients with cancer was 62.0
years, and the average age of patients without diagnosed
cancer was 55.9 years (p = 0.007). There was a higher inci-
dence of antibodies present in those patients diagnosed
Table 1: Occurrence of anti-retinal antibodies in patients with 




Patients with cancer 52
Patients without cancer 141
Patients with Ab 91/193 (47.2 %)
Total Women with Ab 58/111 (63.7 %)
Total Men with Ab 33/82 (36.3 %)
PR Patients with Ab 33/52 (63.5%)
Women with PR and Ab 20/33 (60.6 %)
Men with PR and Ab 13/33 (39.4 %)
AR Patients with Ab 58/141 (41.1%)
Women with AR and Ab 38/58 (65.5 %)
Men with AR and Ab 20/58 (34.5 %)
Ab – antibodies; PR – paraneoplastic syndrome; AR – Autoimmune 
retinopathyBMC Ophthalmology 2004, 4 http://www.biomedcentral.com/1471-2415/4/5
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with cancer (33/52; 63.5%) than in patients with retinop-
athy without cancer (58/141; 41.1%)(p = 0.009). In both
patients with paraneoplastic retinopathy and those with
retinopathy without cancer, more women than men pos-
sessed anti-retinal antibodies (38/58; 65.5% in AR, and
20/33; 60.6% in PR) (Table 1). Considering how many
proteins are present in the retina, the heterogeneity in
antibody recognition was relatively low. Figure 1 shows
the distribution of autoantibody specificity among retinal
proteins grouped according to their molecular weight. The
most frequently observed antibodies among the patients
were the antibodies against retinal α-enolase (28/91),
recoverin (12/91), and p35 (15/91). Antibodies against
recoverin (p23) were present only in the sera of patients
with PR (12/53). Table 2 shows the antibody specificity in
patients with cancer. We observed that antibodies against
unidentified p35 were more common in patients with AR,
while anti-enolase (anti-p46) reactivity was found nearly
equally in the sera of patients with PR and those with
retinopathy without cancer. Proteins of other molecular
weights were also found to react with antibodies from
patients, but their occurrence was lower (Figure 1). These
proteins included antibodies with confirmed specificity
against carbonic anhydrase II (30 kDa), rhodopsin (40
kDa), arrestin (48 kDa), phosphodiesterase (PDE; 88
kDa), and other retinal proteins of unknown identity.
Table 2: Autoantibody specificity in patients with retinopathy and systemic cancer
Patient
# Sex Age Cancer Antibody Specificity
P403 F 62 Endometrium Ca Recoverin [29]; see Fig. 3
P626 F 73 Endometrium Ca Recoverin
P593 F 46 Cervical Ca Enolase
P587 F 81 Ovarian Ca p35, p39, p46, p58
P405 M 62 SCCL Recoverin
P407 M ?? SCCL Recoverin
P409 M 64 SCCL Recoverin; see Fig. 3
P536 F 75 SCCL Recoverin
P619 M 85 SCCL Recoverin
P634 M 84 Benign lung tumor Recoverin
P622 M 68 Lung adenocarcinoma p35
P402 M 84 Colon Ca Recoverin
P692 M 58 Colon p35
P559 F 52 Colon Ca Bipolar cells [13]
P624 F 47 Colon Ca, skin Ca p41
P596 M 66 Bladder Ca Enolase
P568 M 78 Skin melanoma Enolase
P578 F 44 Skin melanoma Enolase
P474 F 35 Skin melanoma Enolase
P618 F 35 Skin melanoma p35=transducin β [14]
P566 M 59 Skin melanoma p35
P614 M 45 Skin melanoma p40
P570 M 70 Squamous cell Ca of the skin Recoverin
P462 F 65 Breast Ca primary, Recurrent Breast Ca Enolase
P488 F 85 Breast Ca Enolase
P529 F 58 Breast Ca Enolase
P726 F 74 Breast Ca Enolase
P718 F 64 Breast Ca in situ Recoverin; see Fig. 3
P547 M 49 Kidney Ca p60
P711 M 64 Tongue Ca, lung sarcoidosis p58
P561 F 55 Cutaneous B-cell Lymphoma Enolase
P651 F 81 Adenocarcinoma of unknown primary discovered in a femoral lymph node Arrestin
P708 F 73 Metastatic adenocarcinoma spread to liver of unknown primary p60
P717 F 75 Metastatic Ca spread to head of unknown primary Enolase
SCCL – small-cell carcinoma of the lung; Ca – carcinomaBMC Ophthalmology 2004, 4 http://www.biomedcentral.com/1471-2415/4/5
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In the control group of 79 sera from healthy subjects with-
out visual loss (47 men, 32 women), we found 15 sera
with anti-retinal antibodies, but in contrast to the retinop-
athy patients, they reacted with multiple retinal proteins
on the blot. In the control group, carbonic anhydrase (a
protein of 30 kDa) was commonly recognized (5/15).
Antibody cytotoxicity
To study the role of antibodies in the pathogenicity of
retinopathy, we randomly selected 28 seropositve sam-
ples from each of the 3 groups of patients: retinopathy
patients with and without cancer, and control subjects.
Purified serum IgGs were tested for their cytotoxic effect
on cultured retinal cells. Figure 2 shows that after a 48-
hour incubation, the cell survival rate was significantly
lower in retinal cells grown in the presence of sera from
patients with PR (62.5%; p < 0.0001) and AR (68.3%; p =
0.0003) than retinal cells grown in the presence of non-
specific sera from control subjects (86.5%).
Follow-up studies
We obtained multiple serum samples from the follow-up
clinic visits of 40 patients, of whom 31 were initially sero-
positive and 9 were seronegative. The repeat samples were
obtained to either monitor worsening symptoms or to
determine the effectiveness of treatment on the antibody
level. Samples that initially tested negative by Western
blotting and immunocytochemistry remained negative 1
to 2 months later. In the seropositive patients, the anti-
bodies persisted over a long period of time – from months
to years. Some patients underwent diverse immunomod-
ulatory treatments, including systemic steroids, immu-
noglobulin infusion (IVIG), or Rituxan (monoclonal
antibodies against B cell CD20), in an attempt to improve
visual symptoms and to reduce the level of anti-retinal
antibodies, but these treatments had varying results. Table
3 summarizes the data from the seropositive patients. Fig-
ure 3 shows the fluctuation of anti-recoverin antibody lev-
els in 3 patients tested in follow-up visits over a long-term.
The level of anti-recoverin antibodies changed over time,
and the rebound in antibody titers was associated with
exacerbations in visual symptoms but not with a recur-
rence of cancer. In one CAR patient (Fig. 3A), anti-recov-
erin antibodies remained at a non-measurable level for
almost 5 years, and then with the worsening of symptoms,
the level considerably increased. However, an extended
work-up for cancer was negative. Similarly, the reoccur-
rence of anti-recoverin antibodies in other patients was
not associated with metastastic events (example in Fig.
3B). Treatment for cancer drastically decreased anti-recov-
erin antibodies (Fig. 3C), which was a result of the
immune cells damage by radiation. However, anti-recov-
erin antibody levels slowly increased when the immune
system recovered, suggesting that cancer treatment has no
direct effect on the level of these antibodies.
Discussion
This study shows that autoantibodies are associated with
autoimmune retinopathies. Autoimmune retinopathy
demonstrates diverse clinical and immunological features
and by expanding the inclusion criteria of patients we
were able to demonstrate that (i) retinopathy patients
with and without cancer, who had unexplained visual
loss, had a high prevalence of autoantibodies against reti-
nal proteins. In our subject population, about half had
anti-retinal autoantibodies, underscoring their frequency
and their potential pathogenic role. Even though not all
patients had antibodies against known autoantigens, such
as recoverin (23 kDa) and retinal α-enolase (46 kDa), a
more general role for autoantibodies can be proposed
based on our findings. Moreover, such high occurrence of
antibodies indicates a need for testing to help with
diagnosis. (ii) An initial seropositive test would be helpful
in diagnosing cancer. (iii) By including the clinical follow-
up seropositive and seronegative patients to establish the
Distribution of autoantibody specificities in patients' sera Figure 1
Distribution of autoantibody specificities in patients' sera. (A) 
Paraneoplastic retinopathy, (B) Autoimmune retinopathy. 
Bars represent the percent of antibody-positive patients with 
a specific antigenic protein. Anti-recoverin antibodies (p23) 
were present only in the sera of patients with paraneoplastic 
retinopathy.BMC Ophthalmology 2004, 4 http://www.biomedcentral.com/1471-2415/4/5
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The effect of antibodies from patients with retinopathy on the survival of retinal cells Figure 2
The effect of antibodies from patients with retinopathy on the survival of retinal cells. E1A.NR3 cells were grown in the pres-
ence of purified human antibodies for 48 hours. AR and PR data were compared with control subjects (n = 28 subjects each 
group).
Table 3: Follow-up studies on seropositive patients
Patients Antibody Testing




No. of Samples No. of positive After treatment
P409 M 64 Recoverin Before 11 See Fig. 3 Negative after chemotherapy and radiation
P785 M 66 Recoverin 5 years after 2 2
P536 F 72 Recoverin Before 2 2
P718 F 64 Recoverin 6 months after 8 See Fig. 3 Reduction after Rituxan
P626 F 73 Recoverin 2 years after 5 2
P426 F 66 Recoverin After 34 See Fig. 3 Negative after Tolpa [29]
P570 M 72 Recoverin Before 2 1
P692 M 58 P35 9 months after 2 1 Negative after systemic steroids
P613 M 68 P35 Before 2 2
P566 M 59 P35 Before 3 2 Negative after INFa/b
P559 F 51 Bipolar cells After 3 1 Negative after chemotherapy [13]
P561 F 55 Enolase 3 months after 5 5 Reduction after IVIG
P474 F 35 Enolase Before 3 1
P593 F 46 Enolase 17 years after 2 2
P660 F 65 Enolase No cancer 3 2
P436 M 43 IPL No cancer 19 8 Negative after IVIG
P662 F 47 P35, p46 No cancer 2 2
P580 M 54 P53, p46 No cancer 3 3 No change after oral steroids
P630 M 40 P35 No cancer 2 2
P579 M 30 P35 No cancer 6 4 No change after oral steroids
P513 F 52 Carbonic anhydrase No cancer 2 2
P577 M 68 P40 No cancer 2 2
P623 F 34 Arrestin No cancer 2 2
P653 F 28 P52 No cancer 3 3BMC Ophthalmology 2004, 4 http://www.biomedcentral.com/1471-2415/4/5
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occurrence in relation to treatment or reoccurrence of
tumor, we showed that, as in other autoimmune diseases,
anti-retinal autoantibodies persisted and the levels fluctu-
ated over a long period of time after the onset of visual
symptoms. Follow-up tests of autoantibody levels can be
used as a biomarker of disease activity associated with
worsening of vision. (iv) Patients with PR retinopathy are
older at the onset of visual symptoms. (v) Because the
occurrence of autoantibodies does not necessarily indi-
cate the presence of an autoimmune disease, findings
from experimental studies are crucial to establish the role
of such antibodies in retinal pathology. Therefore, testing
for specificity, in particular for cytotoxicity, is important
to determine the pathogenic potential of circulating anti-
Longitudinal analysis of serum anti-recoverin antibodies in three CAR patients from serum samples obtained during follow-up  clinic visits Figure 3
Longitudinal analysis of serum anti-recoverin antibodies in three CAR patients from serum samples obtained during follow-up 
clinic visits. Patients' antibody levels were measured by ELISA using recoverin-coated plates. (A) 61-year-old woman (P403) 
diagnosed with endometrial cancer in 1991. The graph presents tests performed after the original publication of this case 
report in 1998 [29]. Tolpa is a natural immunosuppressive drug. (B) 64-year-old woman (P718) who was diagnosed with breast 
carcinoma in 2002 who experienced an onset of visual loss 6 months later. (C) 62-year-old man (P409) who presented with an 
onset of visual loss and antibodies before the diagnosis of SCCL in 1995. Note that chemotherapy and radiation completely 
diminished the presence of antibodies due to the damage of the immune cells. The level of antibodies increased after the 
immune system recovered.BMC Ophthalmology 2004, 4 http://www.biomedcentral.com/1471-2415/4/5
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retinal autoantibodies in high titers, especially light of our
findings that autoantibodies against retinal proteins from
retinopathy patients with and without cancer had similar
cytotoxic effects on retinal cells.
Pathogenic autoantibodies may impact the retina by
influencing function, leading in turn to morphological
damage. Previously, we showed that anti-recoverin
autoantibodies induce apoptotic death of photoreceptor
cells, which leads to retinal degeneration [22,23]. This
study presented the first evidence that the entry of anti-
recoverin antibodies into cells resulted in apoptosis. Anti-
bodies with other specificities have been shown to have
similar effects on retinal cells, for example antibodies
against hsp27 [24], which led to our hypothesis that anti-
body-induced cell dysfunction leads to cell death and ret-
inal degeneration. Thus, autoantibodies can be, and we
believe often are, pathogenic.
The evidence supporting the effects of antibodies on reti-
nal cells are the following findings: a) Autoantibodies
against recoverin specifically labeled retinal photorecep-
tor cells and were internalized by cells causing their apop-
totic death [22]. b) In CAR patients, autoantibodies
against α-enolase induced the apoptotic death of retinal
cells, and in glaucoma patients, autoantibodies against γ-
enolase labeled retinal ganglion cells and induced their
death through apoptosis [21,25]. c) Intravenous injection
or administered to isolated eyecup of anti-arrestin anti-
bodies induced ERG changes [26]. d) Intravitreous injec-
tion of autoantibodies against retinal bipolar cells
induced changes in bipolar cell function as shown by ERG
recording [27]. e) Autoantibodies against p35 and enolase
react with retinal bipolar cells, Müller cells, and ganglion
cells (rather than with photoreceptor cells) [19,21]. Thus,
in the pathogenesis of retinopathy, antibodies may act on
cells other than photoreceptors. Our recent finding that
anti-enolase autoantibodies induce the death of retinal
ganglion cells supports the idea that the broad range of
specificities of antibodies does not exclude their role in
the pathogenicity of autoimmune retinopathy [28]. The
heterogeneity in antigenic recognition may result in com-
plex variations of clinical symptoms.
Conclusions
In conclusion, autoantibodies against retinal proteins
from retinopathy patients with and without cancer had
similar cytotoxic effects on retinal cells. We hypothesize
that, independent of specificity, autoantibody-induced
apoptosis is a pathway to retinal death in AR. However,
the pathogenic mechanisms of retinopathies are complex,
and our understanding of AR is still incomplete. Further
studies are necessary to identify anti-retinal autoantibod-
ies, to test their pathogenic potentials through in vivo and
in vitro methods, and to define clinical and electrophysio-
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